BURNABY, B.C. — LifeLabs union members are urging the B.C. government to review the company’s ownership, one day after ...

GRAIL's groundbreaking Galleri test, detecting 50+ cancers, FDA status, and strategic growth make it a top investment with ...

Following B.C. Premier David Eby’s beefed up made-in-Canada policy announcement on Thursday, a day later, LifeLabs union ...

Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

The comedian Drew Lausch relayed a story about his recent hookup with a doctor (OK brag) and what the experience taught him ...

Quest Diagnostics Inc. closed 8.28% below its 52-week high of $178.87, which the company reached on March 10th.

Quest Diagnostics (DGX) launched a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer’s ...

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

The firm recently announced agreements with Labcorp and Quest Diagnostics to provide its devices for self-collection of vaginal swab specimens.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with German laboratory Labor Dr.